内科理论与实践

内科理论与实践 >

2023 , Vol. 18 >Issue 01: 16 - 17

DOI: https://doi.org/10.16138/j.1673-6087.2023.01.005

规范与实施方案

肾上腺疾病新型冠状病毒感染临床应对指南

展开

收稿日期: 2023-01-15

  网络出版日期: 2023-02-13

基金资助

国家重点研发计划(2021YFC2501600);国家重点研发计划(2021YFC2501601);国家重点研发计划(2021YFC2501603);促进市级医院临床技能与临床创新能力三年行动计划项目(SHDC2020CR2002A);促进市级医院临床技能与临床创新能力三年行动计划项目(SHDC2020CR6015)

收起

Guidelines for clinical management of adrenal disease novel coronavirus infection

Expand

Received date: 2023-01-15

  Online published: 2023-02-13

Fold

本文引用格式

中华医学会内分泌学分会 . 肾上腺疾病新型冠状病毒感染临床应对指南[J]. 内科理论与实践, 2023 , 18(01) : 16 -17 . DOI: 10.16138/j.1673-6087.2023.01.005

参考文献

[1] Clarke SA, Abbara A, Dhillo WS. Impact of COVID-19 on the endocrine system: a mini-review[J]. Endocrinology, 163(1): bqab203.
[2] 国务院联防联控机制综合组. 关于印发新型冠状病毒感染防控方案(第十版)的通知[EB/OL]. 2023. http://www.gov.cn/xinwen/202301/07/content_5735448.htm.
[3] 宁光. 糖皮质激素类药物临床应用指导原则[J]. 中华内分泌代谢杂志, 2012, 28(2):171-202.
[4] Arlt W, Baldeweg SE, Pearce SH, et al. L. Endocrinology in the time of COVID-19: management of adrenal insufficiency[J]. Eur J Endocrinol, 183(1): G25-G32.
[5] 中华医学会内分泌学分会. 原发性醛固酮增多症诊断治疗的专家共识(2020版)[J]. 中华内分泌代谢杂志, 2020, 36(9): 727-736.
[6] Tzoulis P, Waung JA, Bagkeris E, et al. Dysnatremia is a predictor for morbidity and mortality in hospitalized patients with COVID-19[J]. J Clin Endocrinol Metab, 2021, 106(6): 1637-1648.
[7] Tzoulis P, Grossman AB, Baldeweg SE, et al. Management of endocrine disease: dysnatraemia in COVID-19: prevalence, prognostic impact, pathophysiology, and management[J]. Eur J Endocrinol, 2021, 185(4): R103-R111.
[8] Atila C, Sailer CO, Bassetti S, et al. Prevalence and outcome of dysnatremia in patients with COVID-19 compared to controls[J]. Eur J Endocrinol, 2021, 184(3): 409-418.
[9] 中华医学会内分泌学分会. 嗜铬细胞瘤和副神经节瘤诊断治疗专家共识(2020版)[J]. 中华内分泌代谢杂志, 2020, 36(9): 737-750.
[10] Raghavan D, Tan AR, Story ES, et al. Management changes for patients with endocrine-related cancers in the COVID-19 pandemic[J]. Endocr Relat Cancer, 2020, 27(9): R357-R374.
[11] National Institute of Health. Drug-drug interactions between ritonavir-boosted nirmatrelvir (Paxlovid) and concomitant medications[EB/OL]. 2022. https://www.covid19tre-atmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/ritonavir-boosted-nirmatrelvir--paxlovid-/paxlovid-drug-drug-interactions/.
[12] Owen DR, Allerton CMN, Anderson AS, et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19[J]. Science, 2021, 374(6575): 1586-1593.
Options
文章导航

/

〈 〉